

Title (en)

TOPICAL COMPOSITIONS, PROCESS OF LARGE-SCALE MANUFACTURE, AND METHOD OF USE

Title (de)

TOPIISCHE ZUSAMMENSETZUNGEN, VERFAHREN ZUR HERSTELLUNG IM GROSSMASSSTAB UND VERFAHREN ZUR VERWENDUNG

Title (fr)

COMPOSITIONS TOPIQUES, PROCÉDÉ DE FABRICATION À GRANDE ÉCHELLE ET MÉTHODE D'UTILISATION

Publication

EP 4153321 A4 20240424 (EN)

Application

EP 20936216 A 20200522

Priority

US 2020034422 W 20200522

Abstract (en)

[origin: WO2021236108A1] Compositions for the treatment of some orphan diseases and oral mucosal ulcers, many with similarities in terms of their anti-inflammatory and anti-oxidative activities, but also multiple differences in their observed abilities that can be combined to challenge the current, underlying pathophysiology. The orphan diseases of interest are Dupuytren's Contracture, Peyronie's Disease, Scleroderma, Raynaud's (or Renaud's) Phenomenon, chemotherapy/radiation induced oral mucosal ulceration, and aphthous ulcers; and more frequent skin issues of skin damage from cuts, abrasions, and burns; aging skin changes, and toe nail fungus. These can be treated with the disclosed compositions with the proper combination and alteration of ingredients inclusive of alpha-pinene, an aloe vera preparation, and a shea butter preparation. A process for preparation of such ingredients in a water-in-oil emulsion is described herein.

IPC 8 full level

A61Q 19/00 (2006.01); **A61K 8/06** (2006.01); **A61K 8/31** (2006.01); **A61K 8/92** (2006.01); **A61K 8/9789** (2017.01); **A61K 9/00** (2006.01); **A61K 9/06** (2006.01); **A61K 9/107** (2006.01); **A61K 31/015** (2006.01); **A61K 36/15** (2006.01); **A61K 36/185** (2006.01); **A61K 36/886** (2006.01); **A61K 45/06** (2006.01); **A61K 47/14** (2017.01); **A61K 47/32** (2006.01); **A61K 47/44** (2017.01); **A61P 17/00** (2006.01); **A61Q 19/08** (2006.01)

CPC (source: EP)

A61K 8/064 (2013.01); **A61K 8/31** (2013.01); **A61K 8/922** (2013.01); **A61K 8/9789** (2017.08); **A61K 9/0014** (2013.01); **A61K 9/0034** (2013.01); **A61K 9/006** (2013.01); **A61K 9/107** (2013.01); **A61K 31/015** (2013.01); **A61K 36/185** (2013.01); **A61K 36/886** (2013.01); **A61K 45/06** (2013.01); **A61K 47/14** (2013.01); **A61K 47/32** (2013.01); **A61K 47/44** (2013.01); **A61P 17/00** (2018.01); **A61Q 19/08** (2013.01)

C-Set (source: EP)

1. **A61K 31/015 + A61K 2300/00**
2. **A61K 36/886 + A61K 2300/00**
3. **A61K 36/185 + A61K 2300/00**

Citation (search report)

- [XAYI] US 2019151232 A1 20190523 - SCHARP DAVID [US]
- [XAYI] US 2008038219 A1 20080214 - MOSBAUGH JAMES D [US], et al
- [A] US 2015182578 A1 20150702 - CAVALLARO ANTONINO [US]
- [A] US 2013287708 A1 20131031 - SILBERSTEIN TOVA [IL], et al
- [A] US 2005281762 A1 20051222 - MODAK SHANTA M [US], et al
- [A] KR 100873946 B1 20081212 - BIO SPECTRUM INC [KR]
- [A] US 4784842 A 19881115 - LONDON JEAN [US], et al
- [A] US 2016045412 A1 20160218 - DAVIES MATTHEW P [US]
- [A] SCHLEEHAUF BROOKE: "Croda Inc's Cithrol PGTL", COSMETICS & TOILETRIES, 2 July 2019 (2019-07-02), pages 1 - 8, XP055875828, Retrieved from the Internet <URL:https://www.cosmeticsandtoiletries.com/cosmetic-ingredients/natural-sustainable/news/21842803/croda-inc-croda-incs-cithrol-pglt> [retrieved on 20220103]
- See also references of WO 2021236108A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2021236108 A1 20211125; CA 3188531 A1 20211125; EP 4153321 A1 20230329; EP 4153321 A4 20240424

DOCDB simple family (application)

US 2020034422 W 20200522; CA 3188531 A 20200522; EP 20936216 A 20200522